Research Keyword: COVID-19 complications

Healthcare-associated fungal infections and emerging pathogens during the COVID-19 pandemic

mycolabadmin

During the COVID-19 pandemic, fungal infections became a serious complication in hospitalized patients, especially those receiving steroids and other immune-suppressing treatments. Common fungal pathogens like Candida and Aspergillus caused dangerous coinfections, with infection rates varying significantly by region. Current antifungal medications have significant limitations including toxicity and resistance, highlighting the urgent need for new and safer antifungal treatments.

Read More »

Healthcare-associated fungal infections and emerging pathogens during the COVID-19 pandemic

mycolabadmin

During the COVID-19 pandemic, fungal infections became a major health concern, especially in hospitalized patients. Treatments for COVID-19, such as steroids and immunosuppressive drugs, weakened patients’ immune systems, making them vulnerable to serious fungal infections like those caused by Candida auris. Current antifungal medications have significant side effects and many fungi are developing resistance, so scientists are urgently seeking safer and more effective antifungal treatments.

Read More »

Molecular epidemiology, diversity, and antifungal susceptibility profiles of clinical and environmental mucorales: a five-year multicenter study in Iran (2018–2023)

mycolabadmin

This research examined dangerous mold infections (Mucormycosis) that became more common after COVID-19. Scientists identified the types of molds causing these infections in Iran by testing 116 patient samples and 65 soil samples from across the country. They tested these molds against 13 different antifungal medications to find which drugs work best. The results showed that amphotericin B and posaconazole were the most effective medications, and patient samples were more susceptible to these drugs than environmental soil samples.

Read More »
Scroll to Top